microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy

Erin W. Howard and Xiaohe Yang*

Abstract

As de novo and acquired resistance to standard first line endocrine therapies is a growing clinical challenge for estrogen receptor-positive (ER+) breast cancer patients, understanding the mechanisms of resistance is critical to develop novel therapeutic strategies to prevent therapeutic resistance and improve patient outcomes. The widespread post-transcriptional regulatory role that microRNAs (miRNAs) can have on various oncogenic pathways has been well-documented. In particular, several miRNAs are reported to suppress ERα expression via direct binding with the 3’ UTR of ESR1 mRNA, which can confer resistance to estrogen/ERα-targeted therapies. In turn, estrogen/ERα activation can modulate miRNA expression, which may contribute to ER+ breast carcinogenesis. Given the reported oncogenic and tumor suppressor functions of miRNAs in ER+ breast cancer, the targeted regulation of specific miRNAs is emerging as a promising strategy to treat ER+ breast cancer and significantly improve patient responsiveness to endocrine therapies. In this review, we highlight the major miRNA-ER regulatory mechanisms in context with ER+ breast carcinogenesis, as well as the critical miRNAs that contribute to endocrine therapy resistance or sensitivity. Collectively, this comprehensive review of the current literature sheds light on the clinical applications and challenges associated with miRNA regulatory mechanisms and novel miRNA targets that may have translational value as potential therapeutics for the treatment of ER+ breast cancer.

Keywords: Estrogen receptor alpha (ERα), ER+ breast cancer, microRNA (miRNA), miRNA biogenesis, Endocrine therapy resistance, ER-receptor tyrosine kinase (RTK) crosstalk

Background

Estrogen receptor-positive (ER+) breast cancer accounts for nearly 65% of breast cancers. In particular, due to the association of hormone levels and ER activation/regulation, the ER+ breast cancer subtype is particularly prevalent in postmenopausal women taking hormone replacement therapy. The activation of ERα, a major transcription factor, promotes the transcription of a number of target genes that regulate oncogenic processes, including cell cycle progression, cell survival, and epithelial/luminal cell differentiation. Although anti-estrogens, selective ER modulators (SERMs), and selective ER downregulators (SERDs), such as tamoxifen and fulvestrant, are leading treatment strategies that can block mitogenic estrogen activity and have significantly improved ER+ breast cancer patient outcomes, therapeutic resistance remains a significant clinical challenge. Therefore, understanding the mechanisms that regulate estrogen/ER α-mediated oncogenic activity will shed light on novel therapeutic targets to more effectively treat ER+ breast cancer.

Within the past 15 years, substantial research has highlighted the role of microRNA (miRNA) regulation that can contribute to ER+ breast cancer risk or prevention. In particular, studies have not only demonstrated that miRNAs are targets of ERα/hormonal signaling, but have also shown that ERα is a regulatory target of multiple miRNAs. In this review, we highlight miRNA signatures that are associated with ER+ and ER− breast cancer subtypes, as well as key tumor suppressor miRNAs and oncomiRs that are deregulated in ER+ breast cancer and modulate therapeutic resistance. Importantly, we also
discuss the potential clinical applications of novel therapeutic strategies targeting miRNAs, and their role in the treatment of therapeutic-resistant ER\(^+\) breast cancers.

**miRNAs Associated with ER\(^+\) Versus ER\(^-\) Breast Cancer Subtypes**

The identification of miRNA profiles that are associated with specific cancers or predict clinical outcomes has been a major research focus in the past decade or more. In particular, miRNA expression profiling of human breast cancer subtypes, as classified by ER, progesterone receptor, and ErbB2/Her2 receptor statuses, has revealed miRNA signatures that not only correlate with the molecular subtype, but can also serve as potential prognostic markers and indicators of patient responses to facilitate personalized treatment approaches. As summarized in Table 1, numerous reports have identified miRNAs that are differentially expressed in ER\(^+\) versus ER\(^-\) breast cancer samples. Many of the miRNAs that are downregulated in ER\(^+\) breast cancer are tumor suppressor miRNAs, such as miR-206 [1, 2], that function to suppress cell proliferation and survival. The inhibition of tumor suppressor miRNAs consequently contributes to the oncogenic phenotypes associated with ER\(^+\) breast cancer, such as a high proliferative index in the intrinsic Luminal B subtype of ER\(^+\) breast cancers [3]. Indeed, the development of targeted therapeutics to upregulate these particular tumor suppressor miRNAs may serve as a promising strategy to treat ER\(^+\) breast cancer. In contrast, several oncomiRs have consistently been reported to be upregulated in ER\(^+\) breast cancer, such as miR-10b and miR-21 [4–6]. In particular, the tumor suppressor PTEN, which dephosphorylates PIP\(_3\) and in turn blocks PI3K/Akt signaling, is a direct target of many oncomiRs that are overexpressed in ER\(^+\) breast cancer (Table 1). Thus, the attenuation of PTEN-mediated blockage of the PI3K/Akt signaling by the aberrant overexpression of oncomiRs in ER\(^+\) breast cancer contributes to downstream Akt signaling, which promotes oncogenic cell growth, survival, and migration. The targeted inhibition of these oncomiRs could also provide alternative treatment options for ER\(^+\) breast cancer patients. As discussed in the following sections, miRNAs play an integral role in the regulation of estrogen/ER\(_\alpha\) signaling and many miRNAs can also be modulated by ER\(_\alpha\) activation. Yet, miRNA-mediated regulation of ER\(_\alpha\) expression/activity and other oncogenic signaling pathways are linked to resistance to standard first-line endocrine therapies.

**miRNAs and Estrogen/ER\(_\alpha\) Regulation**

**miRNAs that Regulate ER\(_\alpha\)**

Many miRNAs that are associated with ER\(^+\)/ER\(^-\) breast cancer subtypes also directly target or indirectly regulate ESR1/ER\(_\alpha\). To this end, many ESR1-targeting miRNAs are downregulated in ER\(^+\) breast cancer or are upregulated in endocrine therapy-resistant breast cancers (Table 2). In this section, the role of these ESR1-targeting miRNAs in ER signaling regulation will be discussed in context with ER\(^+\) breast carcinogenesis and prevention.

**miR-22**

miR-22 is a classical example of the negative correlation between ESR1-targeting miRNA expression and ER status in breast cancer. As such, miR-22 is downregulated in ER\(^+\) breast cancer cell lines, as well as clinical samples [7]. Studies have also consistently reported that miR-22 can post-transcriptionally inhibit ER\(_\alpha\) expression/function by directly binding to the 3’ UTR of ESR1 [7–9]. Indeed, the overexpression of miR-22 blocks ER\(_\alpha\)-dependent cell proliferation and ER-mediated transcriptional activity in vitro [9]. miR-22 was additionally found to indirectly inhibit ER\(_\alpha\) activity through the direct suppression of the ER\(_\alpha\) transcriptional coactivator, Sp1 [10]. The induction of cellular senescence by miR-22 overexpression also appeared to correlate with a less invasive cellular phenotype in human breast and cervical cancer cell lines [10]. These in vitro data were consistent with results demonstrating that miR-22 overexpression also promotes senescence and reduces the proliferative index of mammary tumor cells in a murine fat pad orthotopic mammary tumor model. In turn, these miR-22-induced cellular responses suppressed overall mammary tumor growth and reduced the appearance of metastatic tumors in vivo [10]. Together, the direct and indirect mechanisms of ESR1/ER\(_\alpha\) inhibition utilized by miR-22 suppress the oncogenic phenotypes associated with downstream ER\(_\alpha\) signaling activity, which makes miR-22 a promising candidate miRNA for therapeutic strategies to treat ER\(^+\) breast cancer.

**miR-206**

miR-206 expression is observably lower in ER\(^+\) breast cancer versus ER\(^-\) breast cancer [1, 2]. Likewise, miR-206 is reported to directly target two binding sites in the 3’ UTR of ESR1 in vitro [11–14]. ER\(_\alpha\) coactivators, NCOA1/SRC1 and NCOA3/SRC3, are also putative targets of miR-206 [14]. As well, miR-206 targets GATA3, a key marker for luminal breast cancer that can activate or be activated by ER\(_\alpha\)s [14, 15]. Indeed, ectopic overexpression of miR-206 significantly repression the oncogenic phenotype associated with ER-mediated cell proliferation and survival, and induces G0/G1 cell cycle arrest in vitro [1, 11, 12, 14]. As a potential mechanism of miR-206-induced G0/G1 cell cycle arrest, it has been recently reported that miR-206 directly targets WBP2, which regulates multiple cell cycle proteins involved in G1 to S phase transition, such as p21, CDK4, and Cyclin D1 [16]. In addition to the suppression of ER\(_\alpha\)-mediated responses and cell cycle regulation,
### Table 1 Differentially expressed miRNAs in ER+ vs. ER− breast cancers and their major direct mRNA targets

| miRNAs          | Expression levels in ER+ (vs. ER−) breast cancer | Direct mRNA targets [117] |
|-----------------|-----------------------------------------------|--------------------------|
| let-7a-c/f      | High [4]                                      | CDK6, KRAS, NRAS, HRAS, ITGB3, NF2, HMGA1/2, EWSR1, DICER, AGO1, LIN28A/B, CASP3/8/9, PARP1, IL6/10, E2F2, CCND1/2, CDC34, CDC25A, EZH2, WNT1, MAPK4/R, IRS2, IGFR1, TGFBR1, AKT2, MYC, Numb |
| miR-9           | Low [118]                                     | ITGB1, ROR1, FOXO1/3, CDH1, MAPK1/3, MMP9, TAZ, NOTCH2, HES1, CBX7, E2F1, RAB34, NFKB1, SIRT1, CCG1, SOCS3, CREB1, DICER1, NF1, CCR4, TGFBR2, BECN1 |
| miR-10a/b       | High [4, 5]                                   | MAP3K7, EPHA4, HOXA1, HOXB3, ACTG1, PTEN, USF2, PI3KCA, SERPINE1, MMP14, NCOA2, CDKN1A/2A, KLF4, PPARα, NF1, PLK1, CCNA2, ZEB1 |
| miR-130a        | Low [2, 4, 11]                                | ESR1, KRAS, PTEN, CTGF, NR3C1, HIF1α, TGFBR2, SMAD2/4, HS2, ATM, DICER, BCL2, IFR2, RUNX1, MEFD2, CBX7, TNFAIP3, FOXN1 |
| miR-22          | Low [7]                                       | PTMS, ERBB3, ARPC5, BMP7, PPARα, ESR1, NCOA1, HDAC4/6, HMGB1, SP1, RABSB5, TET2, CDKNA1, ER, WNT3, SIRT1, IGF1, SIRT1, VEGFA, TP53, CTGF, NR3C1, HIF1α, TGFBR2, SMAD2/4, HS2, ATM, DICER, BCL2, IFR2, RUNX1, MEFD2, CBX7, TNFAIP3, FOXN1 |
| miR-25          | Low [4]                                       | BCL2L1, CC2, KL4, CDKN1C, KAT2B, TP53, CDH1, MDM2, PTEN, EZH2, SMAD7, ERBB2 |
| miR-26a/b       | High [36]                                     | CDK6, CCND2, CCNE1/2, ESR1, CDK6, CCNE1/2, PTEN, EZH2, SERRP1, SMAD1/4, REB1, MAP3K2, GSK3B, NO2, CHD1, FGF9, ATM, HGF, HGF, IGF1, LIN28B, DNM3T8, WEE1, ADAM17, CHEK1, ITGA5, DUSP4/5, NRAS, E2F2, PI3K, JAG1, MYC, GATA4, TAB1, R81, COX2 |
| miR-29b         | High [36]                                     | TGFB1/3, HAC4, COL1A1, COL1A3, COL4A1/2, COL5A2, SP1, CDK6, PPP13B, PTEN, DNM1T1, DNM3T4/8, MCL1, BCL2, VEGFA, TET1/2, CDC2, CDC42, MMP2/9/15/24, ADAM12, BIM1, HMGA2, GSK3B, INF, PI3K, CDN2, AKT/2/3, ITGA6, GATA3, PGDFRA, Gα3C, TRAP, ITGA5, DUSP4/5, NRAS, E2F2, PI3K, JAG1, MYC, GATA4, TAB1, R81, COX2 |
| miR-30a-d       | Low [83]                                      | DT1, SMAD1, CDK6, NOTCH1, Becn1, Sna1, PI3KC3D, PRDM1, ABL1, VIM, ESR2, RUNX2, BCL9, SOX4, TBX3, TP53, NCAM1, DNM1T1, ITGB3, ATF1, CCND2, CCNE1/2, RPA1, TET1, NOTCH1, KLF9, CAT, ATG12, SERPINE1, DLL4, PGDFB, BCL2, Eif5a2, ADAM2, HOXA1, SOCS1/3, RUNX2, CASP3, PAK1, MCL1, FOXO3, EZH2 |
| miR-93          | Low [4, 119]                                  | CDKN1A, TP53INP1, E2F1, VEGFA, ITGB8, KAT2B, TUSC2, PTEN, LAT2, TGFBR2, DAB2, SMAD7, ZBTB4, CIXL8, PDCD4, ANG, PTPN1, NEDD4, MMP3, ZNRF3, FOXA1 |
| miR-100b        | Low [4]                                       | ITCH, APP, CDKN1A, E2F1, KAT2B, RB1, PTEN, AP, CASP7, AXK1, SETD2, SMAD7, STAT3, ZBTB4, TWIST1, HIF1α, TRIM6, RUNX2, DAB2, PTEN1, CYBB, TNF510A/11 |
| miR-130a        | High [4]                                      | HOXA5/10, ATXN1, KL4, PPARG, ESR1, DICER1, RUNX3, RAB5A, SMAD4, TNF, TGFBR2, TBGFI, PPARα, MYC, PTEN, DLL4, MAP3K12, MECP2, MET |
| miR-135b        | Low [120]                                     | APC, KL4, CASR, PPP2R5C, LAT52, SMAD5, MID1, MITCH2, BMP2, TGFBR1, FOXO1 |
| miR-142         | Low [4]                                       | RAC1, ARNTL, TGBFR2/1, BOD1, PROM1, ROKC2, CCN2T, TAB2, HMGA1/B1, PTEN23, TP53INP1, IL1A, HSPB1B, SMAD3, ABCG2, LGR5, ZEB1, SIRT1, HIF1α, SOCS1, PTEN, DOCX6 |
| miR-145         | High [121]                                    | BMPN1, KL4/5, SOX9/2, MUC1, CDKN1A, ITGB8, STAT1, YES1, CLINT1, IRS1/2, VEGFA, HOXA9, MYC, FJ31, INI1B, IGFR2, FZD7, CDK4/6, SERPINE1, ESR1, JAG1, NEDD9, PAK4, ERG, NR4, ADAM17, CDH2, E2P1, LTE1, CD44, BRF, SMAD2/3, TGFBR3, CTNND1, SP1/7, TNFSF13, DODX, ARF6, ADD3, HMGA2, ROCK1, HACD11, SENP1, NAF1, TUG1, TGF2B, EGFR, ACTB |
| miR-148         | High [4]                                      | DNM1T1/8, TG2F, MCL1, IRS1, BCL2, ITAG5/B8, ROCK1, PI3KC3D, NRAS, CSF1, CD258, MAPK3/9, MMP7, WNT1/108, CDKN1B, SERPINE1, SMAD2, MET, USP4, STAT3, ALCAM, TBGFI2, AKT2, BAX, CYBB, NMI1, |
| miR-150         | Low [4]                                       | MYC, MUC2, EGR2, ZEB1, EP300, TP53, CBL, SP1, CREB1, STAT1/5B, CTNNB1, NANOX, MMP14, ZNF350, IGFR1, BIRC5 |
| miR-155         | Low [4]                                       | TAB2, SOCS1/6, MS2H/6, MLH1, DET1, SMAD1/2/5, ZNF662, ZIC3, BACH1, AHC, TRIM32, Rhoa, TP53INP1, SP1, FOXO3, RUNX2, JUN, ETS1, ICAM1, IRAK3, MYB, SKI, SOX6, FAOD, BCL6, NO53, CCNDD1, NFKB1, E2F2, MYC, DOC1T1, RAD51, PTEN, ERBB2, RPTOR, TFAM, STAT1, SIRT1, TP53 |
| miR-185         | Low [4]                                       | Rhoa, CDC42, SOK1, DNM1T4, EPAS1, ARC, NFATC3, VEGFA, MZB1, HMGA1/2, IGFR1, DUSP4, CASP14, EPHB2, SMAD7, TRIM29, TGFBR1, AKT1, CCNE1, CDX6, ATR, EZH2 |
| miR-187         | Low [4]                                       | TNF, BCL6, CRMP1, CYP1B1, FOXA2, ALDH1A3 |
| miR-190         | Low [120]                                     | IGF1, PTEN, BCL2, KCNO5, M2AR, FOXP2 |
miR-206 also directly targets the 3’ UTR of MET, which is associated with aggressive breast cancer phenotypes [12, 17]. Together, these reports further validate the miR-206-induced effects on ERα expression/activation and ER-mediated breast carcinogenesis [14]. The cell cycle and growth-promoting targets of miR-206 also highlight the potential application of miR-206 expression restoration as a potential therapeutic strategy for ER+ breast cancer, particularly the luminal B subtype that is typically characterized by a high proliferative index.

miR-221/222

Various studies have demonstrated that miR-221/222 target oncopgenes, as well as tumor suppressor genes. Of particular importance in ER+ breast cancer, miR-221/222 targets ESR1 [8, 11]. The negative regulation of ESR1/ERα has significant clinical implications related to acquired resistance to endocrine therapies, as discussed later in this review. On the other hand, miR-221/222 can indirectly promote ERα/estrogen signaling through direct inhibition of BECN1/Beclin1, which is a key regulator of autophagy. Beclin1 can induce autophagy and suppress the tumorigenic properties of MCF-7 breast cancer xenografts in vivo [18]. Although cytokine mda-7/IL-24-induced suppression of miR-221 has been found to result in Beclin1-associated autophagic cell death [19], Beclin1 acts as a negative regulator of ERα/estrogen signaling, which may interfere with the efficacy of anti-estrogen therapies [20].

In addition to the regulation of estrogen/ERα signaling, miR-221/222 have a number of tumor suppressor targets, which suggest the oncogenic functional mechanisms of miR-221/222. As a potential mechanism of miR-221/222-associated tumorigenesis, key cell cycle inhibitors have been identified as targets of miR-221/222, which contributes to oncogenic cell cycle progression. In particular, miR-221/222 are negative post-transcriptional regulators of CDKN1B/p27kip1, a cell cycle inhibitor [21, 22]. As such, miR-221/222 overexpression suppresses p27kip1 expression and correspondingly promotes G1/S transition in MCF-7 and MDA-MB-231 breast cancer cell lines [23, 24]. In vitro studies using breast and other
cancer models have further corroborated the oncogenic role of miR-221/222 by demonstrating TIMP3, PTEN, and PUMA, as putative targets of miR-221/222 [25–29]. The inhibition of miR-221/222 targets induces effects on multiple signaling pathways, which results in a range of cellular responses involved in cell proliferation, apoptosis, and invasion/migration. TIMP3 exhibits anti-cancer actions via the inhibition of metalloproteinases, including several ADAMs, which has been shown to block cell migration and invasion associated with cancer cell metastasis. Moreover, PTEN is an inhibitor of the PI3K/Akt pathway and has been well-established as a tumor suppressor. In MCF-7 ER+ breast cancer cells, PTEN suppression via miR-221/222 overexpression was associated with PI3K/Akt-mediated promotion of cell proliferation, migration/invasion, and stemness/self-renewal [28]. Furthermore, PUMA is a pro-apoptotic protein that is regulated by p53. Zhang et al. (2010) found that miR-221/222 knockdown induced PUMA-dependent apoptosis in MCF-7 breast cancer and A549 lung cancer cells [29]. The pro-apoptotic function PUMA was further demonstrated by the concurrent induction of Bax and suppression of Bcl2.

In context with miR-221/222 expression and breast cancer in patients, recent reports indicate that miR-221/222 expression does not significantly correlate with overall and disease-free survival in breast cancer patients not grouped by subtype [30, 31]. However, according to a study by Han et al. (2017), high expression levels of miR-222 in patients with ER+ breast cancer were significantly (P = 0.021) associated with decreased disease-free survival as compared to ER+ breast cancer patients exhibiting low levels of miR-222 [31]. In contrast, the effect of miR-222 expression was not correlated with significant differences in disease-free survival of ER+ breast cancer patients. Thus, these reports provide supportive

### Table 2 miRNAs that regulate ESR1/ERα (Continued)

| miRNA     | Effects on ESR1/ERα and known mechanisms of ER regulation | References |
|-----------|-----------------------------------------------------------|------------|
| miR-217a/c | Suppresses ESR1 expression                                | [11]       |
| miR-520a-e | Suppresses ESR1 expression                                | [11]       |
| miR-548p   | Suppresses ESR1 expression                                | [7]        |
| miR-583    | Suppresses ESR1 expression                                | [7]        |
| miR-590    | Suppresses ESR1 expression                                | [7]        |
| miR-643    | Suppresses ESR1 expression                                | [7]        |
| miR-874    | Suppresses ESR1 expression                                | [7]        |
| miR-885    | Suppresses ESR1 expression                                | [7]        |
| miR-934    | Suppresses ESR1 expression                                | [7]        |
| miR-1231   | Suppresses ESR1 expression                                | [7]        |
evidence that miR-221/222 are key regulators of ER+ breast carcinogenesis.

miRNAs Regulated by Estrogen/ERα
Estradiol/estrogen signaling has been shown to regulate hundreds of genes through direct ERα binding site interaction, transcription factor activation, and miRNA regulation. miRNA microarray analyses have demonstrated that estradiol can upregulate the expression of numerous individual miRNAs and miRNA families, including the let-7, miR-17-92, and miR-200 family members (Table 3) [32]. In this section, several estradiol-regulated miRNAs will be highlighted and the functional implications of their regulation will be discussed in context with ER+ breast carcinogenesis.

miR-21
miR-21 is a well-studied oncomiR with anti-cancer targets, like PDCD4 [33], TIMP3 [34], and PTEN [35], and is overexpressed in human breast cancer tissues as compared to healthy breast tissues [34, 36]. Indeed, miR-21 expression levels increase with tumor grade and invasiveness of the cancer [37]. Thus, given the strong association between miR-21 expression and breast cancer, how miR-21 is regulated is an important question. A recent review by Petrović (2016) postulated that the oncogenic role of miR-21 in breast cancer may lie predominately in the regulation of cancer cell growth and invasion rather than the events that contribute to cancer initiation [38]. Moreover, miR-21 expression was reported to exhibit a 2-fold increase in ER+ breast cancer cells exposed to estradiol [32, 39]. However, in contrast to reports demonstrating that miR-21 is upregulated in response to estradiol, several studies have reported that estradiol suppresses miR-21 expression in vitro [40–43]. In context with the conflicting effects of estradiol on miR-21 expression, ERα binding sites found in the miR-21 regulatory region are key to determining the upregulation or downregulation of miR-21. In particular, Bhat-Nakshatri et al. (2009) found that unliganded ERα suppresses miR-21 expression, whereas ligand-bound/estradiol-activated ERα promotes miR-21 upregulation [32]. Additionally, overexpression of a truncated form of ERα (ERα46) may trigger estradiol-induced miR-21 upregulation [44]. ERα activator, AF-1, was also found to be an integral factor in estradiol-induced miR-21 suppression. Although in vivo data are still missing to fully understand and confirm the effects of estradiol on miR-21 expression, these contrasting reports indicate a complex regulatory mechanism between estradiol and miR-21 that may be differentially regulated at different breast cancer stages.

In regards to the potential of miR-21 as a target for breast cancer inhibition, studies using cell models of ER+ breast cancer have consistently reported that miR-21 inhibition suppresses ER+ breast carcinogenesis [45, 46]. Interestingly, several reports have indicated that non-pharmaceutical interventions can modulate miR-21 expression. For instance, exercise training can reduce the expression of miR-21, which was postulated to contribute to the decreased mammary tumorigenesis observed in in vivo ER+ breast cancer models [47, 48]. These studies found that exercise downregulated miR-21 and rescued the expression of miR-21 targets, including PDCD4. Moreover, Khor et al. (2015) found that exercise training was equally effective as tamoxifen in reducing estradiol levels and ERα expression, and both tamoxifen and exercise training significantly reduced tumor burden in a BALB/c mouse model of ER+ breast cancer [47]. Since PDCD4 downregulation is a major marker of poor prognosis and endocrine therapy resistance in ER+ breast cancer patients [49], the pharmacological, as well as non-pharmacological, suppression of miR-21 represents a promising treatment strategy for ER+ breast cancer patients; however, questions remain to be addressed regarding the regulatory mechanisms that control miR-21 expression during breast carcinogenesis, as well as the mechanism by which exercise training alters miR-21 expression. Uncovering these key mechanisms would significantly advance our understanding of how physiological responses can regulate miRNAs that are associated with oncogenic processes.

miR-7
miR-7 expression is elevated in ER+ breast cancer cell lines and is associated with tumor aggressiveness, as indicated by the positive correlation between miR-7 expression and increased tumor size, grade, and metastasis in ER+ breast cancer patients [8, 50, 51]. In contrast, miR-7 expression is inversely correlated with the invasiveness of breast cancer cell lines in vitro [52]. Moreover, miR-7 is reported to influence the G2/M cell cycle checkpoint and DNA repair via inhibition of key regulators, such as WEE1, GADD45A, TPS3, and ATM [50], which contributes to the reduced proliferative phenotype observed breast cancer cells overexpressing miR-7 [53]. As such, impaired cell cycle and DNA repair associated with miR-7 expression were found to be contributing factors for an accumulation of chromosomal instability. Several groups further explored the mechanisms that regulate miR-7 in ER+ versus ER– breast cancer cell lines and determined that miR-7 is upregulated via estrogen-mediated ERα activation in vitro [8, 39]. As a potential regulatory mechanism that promotes ER dependency for cell proliferation and survival in ER+ breast cancer cells, receptor tyrosine kinases (RTKs), such as EGFR and IGFlR, and their associated ligands, including IRS2, are putative targets of miR-7 [8, 54–56]. However, Cui et al. (2017) recently found that miR-7 overexpression downregulated EGFR and IGFlR protein expression
### Table 3 miRNAs regulated by estrogen/ERα activation

| miRNA | Known mechanisms of regulation by estrogen/ERα | References |
|-------|-----------------------------------------------|------------|
| **miRNAs upregulated by estrogen/ERα** | | |
| let-7a-g/i | Located in the intragenic region of an estradiol-regulated gene | [32, 57] |
| miR-7 | | [8, 39] |
| miR-9 | | [131] |
| miR-17 | ERα-induced MYC/c-MYC upregulation; c-MYC interaction with the miR-17-92 promoter | [32, 39, 57, 59] |
| miR-18a | | [57] |
| miR-19a/b | | [8, 57] |
| miR-20a | ERα-induced MYC/c-MYC upregulation; c-MYC interaction with the miR-17-92 promoter | [8, 39, 57, 59] |
| miR-21 | Contains ERα binding sites in regulatory region | [32, 39, 44, 57, 59] |
| miR-23a | Contains ERα binding sites in regulatory region | [32] |
| miR-24 | | [132] |
| miR-25 | | [39, 57] |
| miR-27b | | [39, 67] |
| miR-29a | | [39] |
| miR-30b/c | Located in the intragenic region of an estradiol-regulated gene | [32] |
| miR-32 | | [57] |
| miR-34c | | [39] |
| miR-92a/b | | [57, 59, 132] |
| miR-93 | Requires estrogen metabolism-mediated oxidative stress | [57, 132, 133] |
| miR-98 | | [32, 57] |
| miR-99b | | [132] |
| miR-101 | | [57] |
| miR-103 | | [32, 132] |
| miR-106a/b | | [8, 57, 59] |
| miR-107 | | [32] |
| miR-124 | | [39] |
| miR-127 | | [39] |
| miR-129 | | [59] |
| miR-148a | | [39] |
| miR-149 | | [39] |
| miR-181d | | [39] |
| miR-191 | | [39, 132] |
| miR-196a | Contains ERα binding site in promoter region | [134] |
| miR-200a-c | | [32, 132] |
| miR-203 | | [32] |
| miR-206 | | [39] |
| miR-210 | | [39] |
| miR-301a | | [39] |
| miR-320a/c | | [132] |
| miR-424 | | [32, 57] |
| miR-450 | | [57] |
| miR-489 | | [57] |
| miR-503 | | [135] |
Table 3 miRNAs regulated by estrogen/ERα activation (Continued)

| miRNA     | Known mechanisms of regulation by estrogen/ERα                                                                 | References |
|-----------|---------------------------------------------------------------------------------------------------------------|------------|
| miR-542   |                                                                                                              | [57]       |
| miR-638   |                                                                                                              | [132]      |
| miR-1275  |                                                                                                              | [132]      |
| miR-1915  |                                                                                                              | [132]      |

miRNAs downregulated by estrogen/ERα

| miRNA     | Known mechanisms of regulation by estrogen/ERα                                                                 | References |
|-----------|---------------------------------------------------------------------------------------------------------------|------------|
| let-7a/c/f/g | Transcriptionally repressed by estradiol-induced ER                                                      | [40, 132]  |
| miR-9     | Located in the intragenic region of an estradiol-regulated gene                                            | [32]       |
| miR-15b   | Mediated by AF-1; Transcriptionally repressed by estradiol-induced ER; Contains ERα binding sites in promoter/regulatory region; Mediated by unliganded ERα | [40–44, 132] |
| miR-22    |                                                                                                              | [57, 59]   |
| miR-23b   | Transcriptionally repressed by estradiol-induced ER                                                        | [40]       |
| miR-26a/b |                                                                                                              | [40, 132]  |
| miR-27a/b | Contains ERα binding sites in regulatory region; Transcriptionally repressed by estradiol-induced ER       | [32, 40, 57] |
| miR-127   |                                                                                                              | [59]       |
| miR-143   |                                                                                                              | [32]       |
| miR-148a  |                                                                                                              | [136]      |
| miR-181a/b/d | Contains ERα binding sites in regulatory region; Transcriptionally repressed by estradiol-induced ER, Mediated by unliganded ERα | [40, 57, 137] |
| miR-198   |                                                                                                              | [57]       |
| miR-200c  |                                                                                                              | [40]       |
| miR-206   |                                                                                                              | [13]       |
| miR-221/222 | Contains ERα binding sites in promoter region                                                        | [12]       |
| miR-302b  |                                                                                                              | [32]       |
| miR-487b  |                                                                                                              | [57]       |
| miR-494   |                                                                                                              | [57]       |
| miR-500   |                                                                                                              | [57]       |
| miR-506   |                                                                                                              | [32]       |
| miR-519e  |                                                                                                              | [8]        |
| miR-524   |                                                                                                              | [32]       |
| miR-584   |                                                                                                              | [57]       |
| miR-663   |                                                                                                              | [57]       |
| miR-671   |                                                                                                              | [57]       |
| miR-1228  |                                                                                                              | [8]        |
| miR-1826  |                                                                                                              | [132]      |

in ER<sup>−</sup> MDA-MB-231 breast cancer cells, but not ER<sup>+</sup> MCF-7 breast cancer cells [52]. Although estradiol mediates miR-7 upregulation to confer ER-dependent cell growth, miR-7 downregulation may contribute to endocrine therapy resistance due to the lack of RTK inhibition, which consequently activates compensatory oncogenic signaling pathways. Alternatively, in ER<sup>−</sup> breast cancers, miR-7 overexpression has been considered as a potential therapeutic strategy to exploit miR-7-mediated suppression of EGFR and IGF1R, which are often overexpressed in triple-negative breast cancer (TNBC). Indeed, miR-7 overexpression can reduce the metastatic potential of TNBC.
cells in vitro [52]. Given the potential breast cancer subtype-specific effects of miR-7 expression, understanding the role of ER-associated regulation of miR-7 and its downstream targets will underscore the clinical applications of targeting miR-7 as novel therapeutic strategies for ER+ breast cancer patients, as well as TNBC patients.

**miR-17 and miR-17-92 Cluster**

miR-17 is a member of the miR-17-92 cluster, which includes the miR-17, miR-19, and miR-92 families. The miR-17 family includes miR-17, miR-18a, and miR-20a; the miR-19 family includes miR-19a and miR-19b; and miR-92 belongs to its own family. Based on several studies, estradiol appears to be a major stimulator of many miRNAs in the miR-17-92 cluster. Specifically, miR-17 and miR-20a have been shown to be upregulated by 1.7–3.36 fold in estradiol-treated ERα breast cancer cell lines via ERα-induced MYC/c-MYC upregulation [32, 39, 57, 58]. Consistent with these in vitro microarray data, Kovalchuk et al. (2007) reported that estradiol exposure upregulated miR-17, miR-20a, and miR-92 in a rat model of estradiol-induced breast carcinogenesis, which was accompanied by oncogenic changes in mammary gland morphology, including lobular hyperplasia with increased alveoli and duct numbers [59]. As well, c-MYC was also found to be significantly upregulated in estradiol-exposed rats, further supporting estradiol/ERα-induced c-MYC upregulation as a major regulatory mechanism of the miR-17-92 cluster. Estradiol-induced modulation of gene and histone methylation may also contribute to these associated changes in miRNA expression. Nevertheless, additional studies are necessary as there is a major gap in our understanding of the mechanisms that mediate estradiol/ERα-associated regulation of miRNAs.

miR-17 is often characterized as an oncomiR given its inhibition of putative targets involved in tumor suppression, including p21 [58, 60]. However, several genes that promote cell growth and survival, such as CCND1, STAT3, and E2F1, are also suppressed by miR-17, as well as miR-20a [58, 61–63]. Thus, miR-17 may have oncogenic or tumor suppressor functions that are dependent on specific cellular conditions that determine the need for cell survival. To note, AIB1 (also known as NCOA3 or SRC3) is a putative target of miR-17 that is implicated in breast carcinogenesis and endocrine therapy resistance, indicating that miR-17 may also function as a regulator of ERα signaling [64–66]. As well, it has recently been reported that induced overexpression of miR-17 can sensitize cells to tamoxifen-mediated apoptosis in vitro [63]. Given the evidence that miR-17 can exhibit functions as both an oncomiR and a tumor suppressor, additional studies are warranted to elucidate the microenvironmental/cellular context that may influence the cancer-promoting or anti-cancer properties of miR-17 and its related family of miRNAs.

**miR-27a/b**

Reports examining the effects of estradiol on miR-27a/b expression have produced conflicting data. For instance, microarray data have indicated that estradiol can elicit a 0.6 to 2.65 fold change in miR-27a/b expression in MCF-7 cells [32, 39, 40, 67]. Despite conflicting in vitro reports, Tang et al. (2012) confirmed that high miR-27a expression and low ZBTB10 expression, a putative target of miR-27a, were associated with poor patient survival [68]. In context with the regulatory role of miR-27a/b in ERα breast cancer, ZBTB10 is a major inhibitor of Sps, including Sp1 [69, 70]. Sp1 interactions with ERα are integral for ERα transcriptional activity; therefore, the indirect regulation of Sp1 via miR-27a may direct the activation or inhibition of ERα activity. miR-27b is also shown to target CYP1B1, a gene that encodes for an enzyme that is important for the hydroxylation of estradiol, which can produce free radicals and lead to DNA damage [71]. Since miR-27b expression is reported at higher levels in normal breast tissues as compared to breast cancer tissues [71], the suppression of miR-27b by estradiol [32] may be a cancer-promoting mechanism that results in the increased expression of CYP1B1 and subsequent DNA damage. Moreover, miR-27b levels are also reduced in tamoxifen-resistant breast cancer cell lines as well as patient samples, which are associated with the increased expression of miR-27b targets NR5A2/LRH1 and CREB1 [67]. The upregulation of NR5A2 has a particularly important oncogenic function as it directly binds to the ERα promoter to stimulate transcription [72] and promote MYC expression [73], which has previously been reported to upregulate the expression of other oncomiRs (i.e. miR-17 and miR-20a) [58]. Thus, further studies are needed to dissect the factors that regulate the balance between the physiological and oncogenic functions of miR-27a/b.

**Feedback Mechanisms that Regulate Estrogen/ER Signaling**

Although it has been well-established that miR-206 directly targets the 3’ UTR of ESR1/ERα in ER+ breast cancer cells [1, 11, 12], Adams et al. (2007) identified a feedback mechanism where estradiol and other ERα agonists can significantly inhibit miR-206 expression, while ERβ agonists promoted miR-206 expression (Fig. 1a) [13]. In contrast, microarray data reported by Masuda et al. (2012) found that estradiol markedly upregulated miR-206 by 3.35-fold in MCF-7 cells, which would consequently inhibit ERα expression and activity [39]. Lee et al. (2013) further suggested a functional role of ERα-mediated miR-206 regulation during physiological mammary gland development as miR-206 was found to
be repressed downstream of ERα, indicating a potential role in ductal growth regulation [74]. Other estrogen/ER-associated miRNAs may also participate in regulatory loops to modulate estrogen/ER signaling. miR-221/222, which directly target ESR1, are other key examples as ERα knockdown in MCF-7 cells revealed that miR-221/222 can be regulated by ERα activity in vitro (Fig. 1b) [12]. Specifically, estrogen-mediated ERα activation recruited corepressors NCoR and SMRT to the transcription start site of miR-221/222. Garofalo et al. (2009) also proposed a mechanism of miR-221/222 upregulation in non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) models involving c-MET/MET-mediated upregulation of the transcription factor AP-1 [25]. This mechanism may be potentially translated to miR-221/222 upregulation associated with ER+ breast cancer models; however, further in vitro and in vivo evidence is warranted.

As previously discussed, miR-17 and miR-27a/b may also be involved in estrogen/ERα pathway regulation. The expression of these miRNAs has been found to be upregulated by estradiol/ERα in numerous reports [32, 39, 58, 59]; however, the attenuation of their putative targets involved in ERα regulation, such as AIB1 by miR-17 and ZBTB10 by miR-27a, results in indirect ERα signaling inhibition and activation, respectively (Fig. 1c) [64, 67, 69]. Additionally, miR-375 is reportedly involved in a feedback mechanism that regulates ERα expression and signaling. Simonini et al. (2010) found that hypomethylation of the miR-375 promoter epigenetically stimulated miR-375 expression, which was positively correlated with ERα expression and activity [75]. The authors further identified RASD1, a negative regulator of ERα, as a direct target of miR-375 (Fig. 1d). In contrast, others have reported that miR-375 can directly target Sp1, an ERα co-activator, in HCC, colorectal, and cervical cancer models [76–78]. Although miR-375-mediated Sp1 regulation has not been verified in breast cancer models, this potential mechanism highlights a facet of miR-375-associated estrogen/ERα signaling regulation. Collectively, miRNA involvement in positive/negative feedback loops that regulate ERα activity can, at times, produce contradictory cellular responses, which further underscores the complexity of these regulatory networks that need to be unraveled to advance the potential development of miRNA-targeting therapeutics for ER+ breast cancer.

miRNAs and Drug Resistance

In ER+ breast cancer, several therapeutic strategies are employed to selectively inhibit estrogen/ERα signaling, including ER antagonists that directly bind to ERα and enzyme inhibitors that block estrogen synthesis. However, de novo and acquired resistance to conventional endocrine therapies can occur in more than 30% of patients [79, 80]. Due to general targeting of estrogen/ER signaling, cross-resistance to multiple endocrine therapies is also a major concern. Therefore, elucidating the mechanisms of therapeutic resistance is integral to preventing and overcoming this significant clinical challenge. Several mechanisms of endocrine therapy resistance have been identified, including decreased ER expression, ER-independent signal transduction, and even miRNA regulation. Notably, miRNAs are promising targets for the novel therapeutic strategies due to the broad range of mRNA targets that ultimately regulate many of the ER-independent mechanisms associated with endocrine therapy resistance. In this section, resistance to tamoxifen, fulvestrant, and aromatase inhibitors will be discussed in context with miRNAs that may confer the resistant phenotype and/or may be promising therapeutic targets to increase patient responsiveness to the first-line endocrine therapies.

Tamoxifen Resistance

As discussed in the previous section, although miR-221/222 are shown to target and inhibit the translation of oncogenic proteins associated with ER+ breast cancer, several studies have linked miR-221/222 expression to tamoxifen resistance. Miller et al. (2008) determined that miR-221/222 expression was positively correlated with resistance to tamoxifen-mediated cell growth inhibition, apoptosis, and cell cycle inhibition in MCF-7 breast cancer cells [23]. In context with the 3′UTR of CDKN1B mRNA as a known target of miR-221/222 [21, 22, 24], CDKN1B mRNA/p27Kip1 protein regulation appears to be an essential mediator of miR-221/222-induced tamoxifen resistance in MCF-7 cells. Indeed, ectopic overexpression of p27Kip1 rescues tamoxifen sensitivity in MCF-7 cells [23]. A report by Wei et al. (2014) suggested that exosomal secretion of miR-221/222 may be a mechanism that confers tamoxifen resistance [81]. Interestingly, secreted exosomes from tamoxifen-resistant MCF-7 cells contained miR-221/222 and could be transferred into tamoxifen-sensitive cells, which rendered the cells resistant to tamoxifen-induced cell growth inhibition and apoptosis. Consistent with miR-221/222 upregulation, ERα and p27Kip1 protein levels were also decreased in the MCF-7 cells exposed to exosomes from tamoxifen-resistant cells. As another potential mediator of tamoxifen resistance, miR-21 was found to be activated by 4-hydroxytamoxifen (4-OHT)- and fulvestrant-mediated blockage of estrogen/estradiol [41]. This in vitro study presented evidence of miR-21 expression as a resistance factor in ER+ breast cancer; nevertheless, additional studies are warranted to fully understand the oncogenic mechanisms of miR-21 and miR-221/222 associated with therapeutic resistance.

ERα expression is a critical factor that mediates tamoxifen resistance. As such, ERα suppression by miRNAs has been shown to block the efficacy of tamoxifen. In this regard, the expression levels of ESR1/ERα-targeting
miRNAs, such as miR-221/222 [8], miR-18a [82], miR-19a/b [83], and miR-22 [9], may predict the clinical responsiveness of ER+ breast cancer patients to tamoxifen. Moreover, Beclin1-overexpressing MCF-7 cells exhibited estradiol-induced colocalization of Beclin1 and ERα, which contributed to decreased sensitivity to tamoxifen derivatives, raloxifene and 4-OHT [20].

Tamoxifen Sensitization

In recent years, several strategies have been proposed to increase breast cancer cell sensitivity to tamoxifen. First, targeted inhibition of miRNAs associated with tamoxifen resistance has provided in vitro evidence of increased tamoxifen sensitivity in ER+ breast cancer cells. As such, miR-221/222 knockdown upregulated TIMP3 mRNA and protein expression, which corresponded with enhanced tamoxifen-induced inhibition of cell viability in MCF-7 ER+ breast cancer cells [26]. To note, miR-221/222 inhibition did not affect the responsiveness of MDA-MB-231 triple-negative breast cancer cells to tamoxifen, which is consistent with the link between miR-221/222 expression, estrogen/ERα signaling, and tamoxifen activity. Furthermore, miR-221/222 silencing in tamoxifen-resistant MCF-7 cells protected wild-type cells from exosomal miR-221/222-induced tamoxifen resistance [81].

The inhibition of known oncomiRs, such as miR-21, has also provided a promising strategy to suppress ER+ breast carcinogenesis and enhance the effects of tamoxifen and other anti-estrogen treatments. Recently, Yu et al. (2016) reported that ectopic suppression of miR-21 via transfection with a miR-21 inhibitor results in Beclin1-mediated autophagic cell death, as well as increased sensitivity to both tamoxifen and fulvestrant, as demonstrated by an increased induction of apoptosis in vitro [46]. Moreover, nanoparticles co-loaded with anti-miR-21 and 4-OHT have shown promising anti-proliferative effects on MCF-7 ER+ breast cancer cells in vitro [84]. As compared to the 4-OHT treatment alone, the anti-miR-21 + 4-OHT nanoparticles induced a significant decrease in cell proliferation, which was accompanied by cell cycle arrest in G2/M phase. Furthermore, miR-34a expression has been reported to suppress miR-21 via the post-transcriptional inhibition of CD24 and Src, which were found to induce miR-21 expression, in vitro breast and colon cancer models [85]. Importantly, CD24 expression has been positively correlated with ERα and ErbB2 status in breast cancer [86], and Src is involved in the phosphorylation/activation and intracellular localization of ERα and subsequent DNA synthesis [87]. Together, these data provide supportive evidence for testing miR-34a mimics and/or miR-21 inhibitors to treat ER+ breast cancer and to overcome tamoxifen resistance.
Alternatively, the induced upregulation of miRNAs that are reportedly downregulated in tamoxifen-resistant cells has been shown to significantly improve ER+ breast cancer cell sensitivity to tamoxifen. For instance, miR-378 is downregulated in tamoxifen-resistant MCF-7 cells and is found at lower levels in human breast cancer tissues as compared to normal adjacent tissues [88]. Low miR-378 expression was further associated with decreased recurrence-free survival in ER+ breast cancer patients taking tamoxifen as an adjuvant therapy [88]. Importantly, key mechanistic data suggest that miR-378-mediated inhibition of GOLT1A, which is involved in the fusion of transport vesicles with the Golgi membrane, plays a critical role in tamoxifen resensitization in vitro, which is further corroborated by clinical data demonstrating increased relapse-free survival in breast cancer patients with low GOLT1A expression. miR-27b is also reportedly downregulated in tamoxifen-resistant ER+ breast cancer cells and patient tumor tissue samples [67, 89]. Zhu et al. (2016) showed that miR-27b-3p is downregulated in tamoxifen-resistant ER+ breast cancer cells [67]. Interestingly, studies have reported conflicting miR-27b regulation by estrogen/estradiol. As previously mentioned, miR-27b was identified as a miRNA that is repressed by estradiol by 0.6 fold in MCF-7 cells [32]. In contrast, a recent report found that estradiol upregulated miR-27b-3p expression, and tamoxifen dose- and time-dependently suppressed miR-27b-3p expression in MCF-7 and T47D cells [67]. Moreover, overexpression via miR-27b mimics significantly enhanced ER+ breast cancer cell sensitivity to tamoxifen-induced cell growth inhibition and apoptosis. miR-27b overexpression also rendered tamoxifen-resistant breast cancer cells sensitive to tamoxifen in both in vitro cell line and in vivo xenograft tumor models [67]. The upregulation of miR-27b sensitization to tamoxifen in ER+ breast cancer cells was further associated with the suppression of direct targets, NR5A2/LRH1 and CREB1, which are implicated in tamoxifen resistance via the induction of ERα and aromatase, respectively [72, 90]. The negative correlation between miR-27b and NR5A2 and CREB1 expression has further been corroborated in human breast cancer tissues from tamoxifen-untreated and tamoxifen-resistant patients, suggesting that miR-27b may be a predictive marker for tamoxifen responsiveness, as well as a potential therapeutic target to overcome tamoxifen resistance [67].

Modulated miR-342 expression is also correlated with tamoxifen resistance/sensitivity in ER+ breast cancer. Numerous studies have consistently reported that miR-342 is downregulated in tamoxifen/4-OHT-resistant breast cancer cell lines and clinical samples [23, 91, 92]. In particular, miR-342 expression was reduced by 55% in 4-OHT-resistant MCF-7 cells as compared to parental cells [23]. Likewise, miR-342 downregulation is associated with tamoxifen treatment failure and decreased overall survival in ER+ breast cancer patients [30, 91]. In preclinical models of tamoxifen resistance, restoring the expression of miR-342 markedly sensitized ER+ breast cancer cells to tamoxifen-mediated cell growth inhibition and apoptosis [91]. Interestingly, He et al. (2013) reported that miR-342 expression is positively correlated with ERα expression in clinical breast cancer samples and breast cancer cell lines, which is proposed as a potential mechanism of enhanced tamoxifen sensitivity in breast cancers [92].

The overexpression of miR-342 is not only a potential biomarker for ER+ breast cancer patient survival and tamoxifen efficacy, but also may serve as a therapeutic target to enhance patient responses to tamoxifen.

The overexpression of EGFR, ErbB2, and other RTKs is linked to tamoxifen resistance as compensatory oncogenic signaling pathways [93, 94]. Therefore, targeted inhibition of these pathways has been presented as a potential strategy to overcome tamoxifen resistance. For example, miR-26a/b are reported to target the 3' UTR of ERBB2 and suppress ErbB2 protein expression in tamoxifen-resistant ER+ breast cancer cells. In particular, miR-26 is suggested to be suppressed by estrogen/estradiol [95] and is found to be downregulated in tamoxifen-resistant breast cancer cells. However, high miR-26a expression is associated with decreased expression of known cell cycle regulatory targets, including Cyclin E1, EZH2, and Cdk1, and positive clinical outcomes in patients with metastatic breast cancer taking tamoxifen [96]. Overexpression of the tumor suppressor miR-34a has also been reported to suppress ErbB2 expression and breast cancer cell growth and invasion [97]. Given the oncogenic function of ErbB2 in acquired tamoxifen resistance, miR-34a expression may be a prognostic target to predict tamoxifen responsiveness in ER+ breast cancer patients. In addition, the knockdown of Beclin1, a target of miR-221 [19], has been reported to suppress ErbB2 expression and restore tamoxifen sensitivity in resistant MCF-7 cells in vitro [98]. Consistently, clinical data from ER+ breast cancer patients taking tamoxifen have demonstrated that high Beclin1 expression is correlated with decreased patient survival [98]. Based on reports highlighting the oncogenic role of Beclin1 in ER+ breast cancer, miR-221-induced inhibition of Beclin1 would theoretically inhibit ER+ breast carcinogenesis and promote tamoxifen sensitivity in ER+ breast cancers. Nevertheless, the anti-cancer mechanism involving Beclin1 knockdown, in context with reports indicating the cancer-promoting activities of miR-221/222, further adds to the complex role of miR-221/222 in ER+ breast cancer promotion and inhibition.

**Fulvestrant Resistance**

Due to the different anti-cancer mechanisms of tamoxifen and fulvestrant (also known as ICI-182,780 or Faslodex),
Zhou et al. (2018) recently reported that miRNA profiles generally differ between fulvestrant- and tamoxifen-resistant MCF-7 breast cancer cells [99]. Nevertheless, there are some miRNAs that are associated with resistance to both therapeutic agents because of the broad range of miRNA targets. As such, miR-21 overexpression has also been found to confer tamoxifen and fulvestrant resistance through the inhibition of its direct targets, including PTEN [46]. Interestingly, treatment with fulvestrant can upregulate miR-21 expression [49], which indicates that miR-21 may have a critical role in the development of fulvestrant resistance.

Other examples of miRNAs that are involved in both tamoxifen and fulvestrant resistance are miR-221/222. miR-221/222 are upregulated in both tamoxifen- and fulvestrant-resistant MCF-7 cells, but to a greater extent in the fulvestrant-resistant cell line, and confer the resistant phenotype [100]. Similar to the report indicating that exosomes can transfer miR-221/222 to promote tamoxifen resistance in nearby cells, microvesicles containing miR-221 produced from cancer-associated fibroblasts can transfer fulvestrant resistance to non-tumor cells in an IL6-dependent manner [101]. Fulvestrant, but not tamoxifen, also significantly upregulates miR-221/222 expression in parental MCF-7 cells, which may be an indicator of the development of fulvestrant-resistance. As well, miR-221/222 upregulation promotes fulvestrant resistance via multiple pathways, including the targeted inhibition of ERα and p27kip1. The inhibition of ERα upon miR-221/222 overexpression consequently induces ERα-independent cell growth, which is a mechanism that confers fulvestrant resistance. RTK and Wnt/β-catenin pathways have been implicated in ERα-independent cell growth in fulvestrant-resistant cells [100, 102]. Particularly, the expression of critical genes involved in the Wnt/β-catenin pathway, including CTNNB1, LRIP6, and WNT11, was previously found to be upregulated in fulvestrant-resistant MCF-7 cells, which coincided with hypomethylation of their gene promoters [102]. Moreover, β-catenin overexpression was found to confer fulvestrant resistance, but to a lesser extent than miR-221/222 overexpression, suggesting that miR-221/222 regulation of other targets is necessary to induce fulvestrant resistance. Together, these reports indicate that perhaps miR-221/222 may functionally regulate Wnt/β-catenin signaling through an epigenetic mechanism that modulates promoter methylation.

More recently, the activation of other oncogenic signaling pathways has been connected to miR-221/222 expression and acquired fulvestrant resistance, including the upregulation of key markers in the TGFβ, Notch, Jak-STAT, MAPK, and p53 signaling pathways [100]. Furthermore, miR-221/222 overexpression promoted TGFβ-induced cell survival in parental MCF-7 cells, whereas miR-221/222 knockdown enhanced the tumor suppressor activities of TGFβ with significantly decreased cell survival in fulvestrant-resistant MCF-7 cells. Thus, Rao et al. (2011) postulated that miR-221/222 may have an additional regulatory role that preferably stimulates the oncogenic function of TGFβ to promote fulvestrant-resistant breast cancer cell growth [100].

Fulvestrant Sensitization

Integrative computational analyses of miRNA-gene expression in endocrine therapy-resistant breast cancer cell lines have revealed a miR-222-CDKN1B/p27kip1 expression network that is conserved in both tamoxifen-resistant and fulvestrant-resistant MCF-7 cells [103]. Similar strategies to enhance ERα breast cancer cell sensitivities to tamoxifen and fulvestrant are being tested. The knockdown of oncogenic miR-221/222 in fulvestrant-resistant MCF-7 cells resulted in the concurrent inhibition of cell growth and colony formation, as well as the upregulation of p27kip1 upon fulvestrant treatment [100]. In addition to the well-studied regulatory function of miR-221/222 on p27kip1 and ERα expression, miRNA expression profiling revealed that 428 gene probes were upregulated and 224 gene probes were downregulated in response to miR-221/222 knockdown in fulvestrant-resistant MCF-7 cells. These data highlight the widespread and complex functional role of miR-221/222 in fulvestrant resistance, and uncover novel pathways or key mediators, such as Wnt/β-catenin, TGFβ, EGFR, and ErbB2, that may be valuable targets for future therapeutic development or combined treatment strategies. Importantly, the targeted inhibition of EGFR, ErbB2, and β-catenin in tamoxifen-resistant and fulvestrant-resistant cells has demonstrated sensitization to the growth inhibitory effects proportional to the degree of phosphorylation/activation of these targets in the parental and resistant cells [102]. Given the correlation between these oncogenic compensatory pathways that promote ERα-independent cell growth and tamoxifen/fulvestrant resistance, the targeted inhibition of miR-221/222 expression is a promising strategy to prevent the acquisition of fulvestrant resistance and even treat fulvestrant-resistant breast cancer patients. The regulation of autophagy is emerging as another potential strategy to overcome fulvestrant resistance. It was recently reported that the combined inhibition of EGFR/ErbB2 (via lapatinib) and c-ABL (via imatinib) in fulvestrant-resistant breast cancer cells significantly inhibited cell growth and autophagy [104]. These anti-cancer effects were found to be associated with the upregulation of miR-375, which has previously been linked to PDK1/Akt/mTOR-independent inhibition of autophagy, as indicated by decreased autophagosome formation, ATG7 gene expression, and LC3-II protein expression, in HCC in vitro and in vivo [76]. In contrast to the anti-cancer effects resulting from miRNA-induced suppression of autophagy in fulvestrant-resistant cells, a report using parental MCF-7 cells found that miR-21 knockdown increased autophagic
cell death via activation of its direct target PTEN and subsequent inhibition of the PI3K/Akt/mTOR pathway to enhance sensitivity to tamoxifen and fulvestrant [46]. To note, the effects of miR-21 knockdown on autophagy in resistant breast cancer cells has not been investigated. Moreover, increased autophagy has been reported in cells treated with 4-OHT and fulvestrant, which may be a potential mechanism that leads to the acquisition of therapeutic resistance [105]. miR-214 overexpression was shown to suppress 4-OHT- and fulvestrant-induced autophagy in MCF-7 cells through the inhibition of its direct target UCP2. Importantly, miR-214-mediated suppression of UCP2 led to the inhibition of the PI3K/Akt/mTOR pathway [105]. Based on these findings, the regulation of autophagy may have different consequences in context with the therapeutic sensitivity/resistance of the cells, which warrants further investigation. Advancing our understanding of the role of autophagy in fulvestrant/tamoxifen resistance will support the development of novel strategies that modulate autophagy to prevent or overcome endocrine therapy resistance.

miRNA-Regulated Pathways Associated with Aromatase Inhibitor (AI) Resistance

AIs, such as letrozole and anastrozole, are typically prescribed to postmenopausal ER+ breast cancer patients. However, the prolonged estrogen deprivation in these patients can lead to acquired AI resistance, which is a critical clinical challenge. Emerging studies have determined that, like tamoxifen and fulvestrant resistance, AI resistance can also be mediated by miRNAs in ER+ breast cancer. Although the number of studies examining the connection between AI resistance and miRNA regulation in ER+ breast cancer is generally limited, several specific pathways appear to be the main targets associated with miRNA-mediated regulation of AI resistance.

According to a miRNA microarray using letrozole- and anastrozole-resistant MCF-7 cells, Vilquin et al. (2015) reported that both miRNA signatures in the resistant cells were associated with the regulation of the various signaling pathways, including MAPK signaling, focal adhesion, insulin signaling, ErbB signaling, and mTOR signaling pathways that converged on Akt regulation [106]. The microarray analyses determined that miR-125b, miR-205, and miR-30a were all significantly upregulated, while miR-424 was significantly downregulated, in both AI-resistant cell lines as compared to the sensitive cells. Interestingly, miR-125b and miR-205 overexpression and miR-424 suppression were able to confer resistance to both letrozole and anastrozole, as well as promote mammosphere/stem cell self-renewal, which may contribute to the aggressive nature of the resistant cells [106]. The activation of the PI3K/Akt/mTOR pathway appeared to be a critical mechanism of miR-125b/miR-205/miR-424-mediated AI resistance. In contrast, the targeted suppression of miR-125b/miR-205 and overexpression of miR-424 may rescue the sensitivity of the cells to AIs. Clinical data demonstrating that miR-125b overexpression is correlated with decreased relapse-free survival in primary ER+ breast cancer samples further support the role of miRNAs, particularly miR-125b, miR-205, and miR-424, in AI resistance [106]. Compensatory activation of ErbB2 and downstream MAPK and Akt signaling in AI-resistant ER+ breast cancer cells resulted in the upregulation of miR-21 and downregulation of its target PDCD4 [49]. In clinical cohorts of ER+ breast cancer patients, PDCD4 expression is strongly linked to patient outcomes, as demonstrated by patients with low PDCD4 expression levels having poor disease-free survival and increased tumor grade. As PDCD4 is a direct target of miR-21, targeted inhibition of miR-21 significantly reduced cell proliferation in AI/letrozole-resistant MCF-7 cells in vitro [49], demonstrating that miR-21 may also be a potential target to treat AI resistance. Collectively, these preclinical and clinical data provide promising evidence regarding the potential clinical application of the targeted regulation of these miRNAs to overcome AI resistance and underscore the functional contribution of PI3K/Akt/mTOR pathway activation in AI resistance.

The TGFβ signaling pathway is another major pathway that can be modulated by miRNAs to promote AI resistance. Particularly, TGFβRI is identified as a direct target of miR-128a, which is overexpressed in letrozole-resistant MCF-7 cells [107]. TGFβ induces a growth inhibitory effect in letrozole-sensitive cells, but does not significantly alter cell growth in the resistant cells, suggesting that the miR-128-mediated regulation of TGFβRI may contribute to the differential responses in the letrozole-sensitive and -resistant cell lines. In turn, suppression of miR-128a was found to inhibit TGFβRI in letrozole-resistant cells, which promoted the growth inhibitory effects of TGFβ. As the correlation between miR-128a expression and letrozole resistance has only been reported in in vitro cell models, further examination in additional preclinical models and verification in clinical datasets are needed to substantiate the clinical value of miR-128a as a potential therapeutic target or marker for AI resistance.

Moreover, AI-resistant MCF7-LTED (long-term estrogen deprivation – an in vitro model of AI resistance) cells characteristically utilize glycolytic metabolism, but can switch to oxidative phosphorylation when the glycolytic pathway is impaired. The ability of AI-resistant cells to undergo this metabolic pathway reprogramming has been linked to estradiol-mediated upregulation of miR-155 [108]. Therefore, the expression of miR-155, which is reported to target hexokinase 2 (HK2) through the direct inhibition of miR-143 in head and neck squamous cell carcinoma models, is implicated in clinical AI resistance [108, 109]. To note, HK2 is a key primer for
glycolysis. Indeed, targeting the miR-155/miR-143-HK2 axis may be a promising strategy to overcome letrozole resistance. As well, miR-155 expression may serve as a prognostic biomarker to predict the clinical responsiveness to AIs in women with ER⁺ breast cancer.

Mechanisms that Regulate miRNA Biogenesis in ER⁺ Breast Cancer

As discussed previously, estrogen/ERα signaling can modulate the expression of various oncogenic and tumor suppressor miRNAs. However, the specific regulatory mechanisms have not been fully uncovered. In particular, the regulation of miRNA biogenesis and its functional machinery is a key mechanism that controls miRNA expression. In this section, the mechanisms of regulation and consequences of deregulated miRNA biogenesis will be discussed in context with ER⁺ breast carcinogenesis.

The process of miRNA biogenesis and the components that form essential complexes, such as Drosha, DGCR8, Dicer1, and Ago2, have been extensively studied. Particularly, the oncogenic consequences of miRNA biogenesis deregulation have been well-documented [110–112]. Estrogen/ERα can modulate key machinery involved in miRNA biogenesis, which may have key functional consequences in ER⁺ breast cancer. For instance, Dicer, a cytoplasmic endonuclease required for cleavage of the hairpin loop from the pre-miRNA, can be induced by estradiol as Dicer is reported to associate with an ERα binding site, which promotes Dicer mRNA transcription [32]. Accordingly, Dicer expression is upregulated in ER⁺ breast cancer [4]. To note, Dicer expression can be modulated by miRNAs, including miR-221/222, miR-29a, and miR-200c [8]. Conversely, Ago1/2 were found to be downregulated in ER⁺ breast cancers versus ER⁻ breast cancers despite up-regulation of other components of the RISC (i.e. Dicer and TRBP) [4, 113]. Drosha expression was also significantly lower in ER⁺ breast cancer samples. As well, it has been proposed that activated ERα may interfere with the Drosha-DGCR8 microprocessor complex that is responsible for pri-miRNA cleavage [114]. Nevertheless, as a potential functional consequence of estradiol-mediated Dicer induction and the activation of other cell signaling pathways that stimulate miRNA biogenesis, the overall expression level of miRNAs is significantly increased in ER⁺ breast cancer cell lines and patient samples [4, 8]. Given the differential expression/regulation of miRNA processing machinery in ER⁺ breast cancer, it is critical to understand the factors that regulate these key components and their specific role in cancer promotion or suppression. Overall, defective miRNA biogenesis and machinery appear to be an important mechanism that ultimately contributes to ER-associated breast carcinogenesis. Thus, further exploration of these regulatory mechanisms is necessary to advance our understanding of how miRNA gene regulation can contribute to breast cancer, and may also reveal novel therapeutic strategies/targets for treating ER⁺ breast cancer.

Role of miRNAs in ER-RTK Crosstalk Regulation in Breast Cancer

Studies unraveling the complex oncogenic signal transduction networks associated with breast cancer initiation and progression have revealed that crosstalk between key signaling pathways is an important factor contributing to breast carcinogenesis and resistance to therapeutic agents. In particular, crosstalk between the ER and RTK pathways has emerged as a critical mechanism of compensatory pathway activation, particularly in endocrine therapy-resistant ER⁺ breast cancers [115]. The RTK family includes a number of growth factor-mediated receptors, such as IGF1R, EGFR, and ErbB2/Her2, that are reported to promote several hallmarks of breast cancer. Arpino et al. (2005) found that high ErbB2/Her2 and EGFR expression was independently associated with a significant decrease in disease-free survival in ER⁺ breast cancer patients taking tamoxifen [116]. Importantly, studies have found that several miRNAs can regulate targets involved in both the ER and RTK pathways, thus repressing ER-RTK crosstalk. Of particular importance, miRNAs involved in the regulation of ER-RTK crosstalk may serve as leading candidates for the development of novel miRNA-based breast cancer therapies targeting multiple oncogenic pathways.

Summary and Future Perspectives

Our review of miRNA-associated hormonal signaling in ER⁺ breast cancer has revealed a complex signaling network that can regulate ER⁺ breast cancer progression and response to anti-estrogen therapies. Although substantial in vitro data in conjunction with human miRNA/mRNA expression profiles have uncovered key mechanisms of miRNA regulation, functional consequences, and potential therapeutic targets, further in vivo evidence from animal models of ER⁺ breast cancer are necessary to support the clinical application and development of miRNA-targeted therapeutics. These advances will ultimately help to identify prospective miRNA candidates for nucleic acid-based therapeutics, such as antagonomiRs or miRNA sponges to suppress oncomiRs and miRNA mimics to promote the tumor suppressor miRNAs, which will further guide the clinical development and application of miRNA-based therapeutic strategies for the treatment of ER⁺ breast cancer. Advancing our mechanistic understanding of de novo and acquired resistance to endocrine therapies and miRNA regulation will also facilitate the identification of miRNA biomarkers and the development of miRNA inhibitors/activators to enhance the efficacy of current endocrine therapies and overcome therapeutic resistance in ER⁺ breast cancer patients.
Abbreviations
4-OHT: 4-hydroxytamoxifen; AI: Aromatase inhibitor; ER*: Estrogen receptor-positive; ERα: Estrogen receptor alpha; HCC: Hepatocellular carcinoma; HK2: Hexokinase 2; LTED: Long-term estrogen deprivation; miRNA: microRNA; NSCLC: Non-small cell lung cancer; RTK: Receptor tyrosine kinase; SERD: Selective estrogen receptor downregulator; SERM: Selective estrogen receptor modulator; TNBC: Triple-negative breast cancer

Funding
This work was supported in part by an R21 grant from the NIEHS (SR21 ES025337-02), a U54 grant from the NIAAA (U54 AA019765–08), and a U54 grant from the NIMHD (1 U54 MD012392–01).

Authors’ Contributions
EWH wrote the manuscript. XY contributed to conceptualization and supervision. All authors read and approved the final manuscript.

Ethics Approval and Consent to Participate
Not applicable.

Consent for Publication
Not applicable.

Competing Interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 8 August 2018 Accepted: 29 August 2018
Published online: 11 September 2018

References
1. Kondo N, Toyama T, Sugihara H, Fuji Y, Yamashita H. MiR-206 expression is down-regulated in estrogen receptor α-positive human breast cancer. Cancer Res. 2008;68:5004–8.
2. Yoshimoto N, Toyama T, Takahashi S, Sugihara H, Endo Y, Iwasa M, Fuji Y, Yamashita H. Distinct expressions of microRNAs that directly target estrogen receptor α in human breast cancer. Breast Cancer Res Treat. 2011;130:331–9.
3. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies SR, Swiatle PJ, Cottingham S, et al. Mit induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci. 2009;106:12909–14.
4. Liang XH, Yu J, Brown K, Levine B. Beclin 1 contains a leucine-rich nuclear export signal that is required for its autophagy and tumor suppressor function. Cancer Res. 2001;61:3443–9.
5. Pradhan AK, Takuladak S, Bhoopathi P, Shen X-N, Emdad L, Das SK, Sarkar D, Fisher PB. miR-7a–7b–24 mediates Cancer cell–specific death via regulation of miR-221 and the Beclin-1 Axis. Cancer Res. 2017;77:949–59.
6. John S, Nayvelt I, Hsu H-C, Yang P, Liu W, Das GM, Thomas T, Thomas T. Regulation of estrogenic effects by beclin 1 in breast cancer cells. Cancer Res. 2008;68:7855–63.
7. Le Sage C, Nagel R, Egan DA, Schier M, Mesman E, Mangiola A, Anile C, Mannia G, Mercatelli N, Ciafre SA, et al. Regulation of the p27Kip1 tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 2007;26:3699–50.
8. Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Levine V, Barbosa-Morais NL, Teschendorff AE, Ellis IO, et al. MicroRNA (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer. 2007;14:791–8.
9. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, Jacob S, Majumder S. MicroRNA-211/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem. 2008;283:29897–903.
10. Li Y, Liang C, Ma H, Zhao Q, Li Y, Xiang Z, Li L, Qin J, Chen Y, Cho WC, et al. miR-221/222 promotes S-phase entry and cellular migration in control of basal-like breast cancer. Molecules. 2014;19:712–37.
11. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh S-S, Nagienuk A, Taccioli C, Pichiorri F, Alder H, Sciscione C, et al. miR-221/222 regulates TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell. 2009;16:498–509.
12. Gan R, Yang Y, Yang X, Zhao L, Li J, Meng Q. Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIM3. Cancer Gene Ther. 2014;21:290–6.
13. Petrovic N, Davidovic R, Jovanovic-Cupic S, Krajnovic M, Petrocca F, Alder H, Croce CM, Fusco A. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer. 2007;14:791–8.
14. Pradhan AK, Takuladak S, Bhoopathi P, Shen X-N, Emdad L, Das SK, Sarkar D, Fisher PB. miR-7a–7b–24 mediates Cancer cell–specific death via regulation of miR-221 and the Beclin-1 Axis. Cancer Res. 2017;77:949–59.
15. Pradhan AK, Takuladak S, Bhoopathi P, Shen X-N, Emdad L, Das SK, Sarkar D, Fisher PB. miR-7a–7b–24 mediates Cancer cell–specific death via regulation of miR-221 and the Beclin-1 Axis. Cancer Res. 2017;77:949–59.
16. John S, Nayvelt I, Hsu H-C, Yang P, Liu W, Das GM, Thomas T, Thomas T. Regulation of estrogenic effects by beclin 1 in breast cancer cells. Cancer Res. 2008;68:7855–63.
17. Le Sage C, Nagel R, Egan DA, Schier M, Mesman E, Mangiola A, Anile C, Mannia G, Mercatelli N, Ciafre SA, et al. Regulation of the p27Kip1 tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 2007;26:3699–50.
18. Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Levine V, Barbosa-Morais NL, Teschendorff AE, Ellis IO, et al. MicroRNA (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer. 2007;14:791–8.
19. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, Jacob S, Majumder S. MicroRNA-211/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem. 2008;283:29897–903.
20. Li Y, Liang C, Ma H, Zhao Q, Li Y, Xiang Z, Li L, Qin J, Chen Y, Cho WC, et al. miR-221/222 promotes S-phase entry and cellular migration in control of basal-like breast cancer. Molecules. 2014;19:712–37.
21. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh S-S, Nagienuk A, Taccioli C, Pichiorri F, Alder H, Sciscione C, et al. miR-221/222 regulates TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell. 2009;16:498–509.
22. Gan R, Yang Y, Yang X, Zhao L, Li J, Meng Q. Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIM3. Cancer Gene Ther. 2014;21:290–6.
23. Petrovic N, Davidovic R, Jovanovic-Cupic S, Krajnovic M, Petrocca F, Alder H, Croce CM, Fusco A. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer. 2007;14:791–8.
microRNAs control estradiol response in breast cancer cells. Nucleic Acids Res. 2009;37:4850–61.
33. Franken LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem. 2008;283:1026–33.
34. Song B, Wang C, Liu J, Wang X, Lv L, Wei L, Xie L, Zheng Y, Song X. MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J Exp Clin Cancer Res. 2010;29:29.
35. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in breast cancer. Cell Death Differ. 2007;14:1175–82.
36. Ishii K, Inoue A, Nakamura J, Katsuki Y, Nakamura M, Asano H, Okubo Y, Kozaki S. miR-21 induces cell proliferation and suppresses apoptosis in breast cancer cells. Cancer Lett. 2009;274:148–56.
37. Petrović M, Racovita D, Prisecaru M, Cazaciu L, Mihai C, Oprea M, Horașu T, Mihailă A. miR-21 expression is associated with tamoxifen resistance in breast cancer patients. J Cell Mol Med. 2010;14:1738–46.
38. Petrović M, Racovita D, Prisecaru M, Cazaciu L, Mihai C, Oprea M, Horașu T, Mihailă A. miR-21 expression is associated with tamoxifen resistance in breast cancer patients. J Cell Mol Med. 2010;14:1738–46.
39. Hoekstra WG, Jazouli H, Van Zijl CF, Te Boekhorst JA, Bussink J, van den Bent MJ, Boerman OC, van der Kwast TH. miR-21 expression is associated with tamoxifen resistance in breast cancer patients. J Cell Mol Med. 2010;14:1738–46.
40. Hoekstra WG, Jazouli H, Van Zijl CF, Te Boekhorst JA, Bussink J, van den Bent MJ, Boerman OC, van der Kwast TH. miR-21 expression is associated with tamoxifen resistance in breast cancer patients. J Cell Mol Med. 2010;14:1738–46.
41. Hoekstra WG, Jazouli H, Van Zijl CF, Te Boekhorst JA, Bussink J, van den Bent MJ, Boerman OC, van der Kwast TH. miR-21 expression is associated with tamoxifen resistance in breast cancer patients. J Cell Mol Med. 2010;14:1738–46.
42. Hoekstra WG, Jazouli H, Van Zijl CF, Te Boekhorst JA, Bussink J, van den Bent MJ, Boerman OC, van der Kwast TH. miR-21 expression is associated with tamoxifen resistance in breast cancer patients. J Cell Mol Med. 2010;14:1738–46.
43. Hoekstra WG, Jazouli H, Van Zijl CF, Te Boekhorst JA, Bussink J, van den Bent MJ, Boerman OC, van der Kwast TH. miR-21 expression is associated with tamoxifen resistance in breast cancer patients. J Cell Mol Med. 2010;14:1738–46.
44. Hoekstra WG, Jazouli H, Van Zijl CF, Te Boekhorst JA, Bussink J, van den Bent MJ, Boerman OC, van der Kwast TH. miR-21 expression is associated with tamoxifen resistance in breast cancer patients. J Cell Mol Med. 2010;14:1738–46.
72. Thrulicvelt PT, Lai C-F, Hua H, Thomas RS, Hurtado A, Hudson W, Bayly AR, Kyle FJ, Periyasamy M, Photiou A, et al. The liver receptor homolog-1 regulates estrogen receptor expression in breast cancer cells. Breast Cancer Res Treat. 2011;127:385–96.
73. Bianco S, Brunelle M, Jangal M, Magnani L, Gévry N. LRH-1 governs vital transcriptional programs in endocrine-sensitive and resistant breast cancer cells. Cancer Res. 2014;74:2015–25.
74. Lee MJ, Yoon K-S, Cho K-W, Kim K-S, Jung H-S. Expression of miR-206 during the initiation of mammary gland development. Cell Tissue Res. 2013;353:425–33.
75. Simonis PJR, Breiling A, Gupta N, Malekpour M, Youns M, Omranipour R, Malekpour F, Vollina S, Croce CM, Najmabadi H, et al. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor a in breast cancer cells. Cancer Res. 2010;70:1975–84.
76. Chang Y, Yan W, He X, Zhang L, Huang H, Nace G, Geller DA, Lin J, Tsung A. miR-375 inhibits autophagy and reduces viability of hepatocellular carcinoma cells under hypoxic conditions. Gastroenterology. 2012;143:177–87.
77. Liu X, Wang J, Dong Y. The inhibitory effect of miR-375 targeting sp1 in colorectal cancer cell proliferation. Eur Rev Med Pharmacol Sci. 2018;22:405–11.
78. Wang F, Li Y, Zhou J, Xu J, Peng C, Ye F, Shen Y, Lu W, Wan X, Xie K. miR-375 is down-regulated in squamous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SPI1. Am J Pathol. 2011;179:2580–8.
79. EBCTCG EBCTCG, Davies C, Godwin J, Gray R, Clarke M, Cutter D, Cittelly DM, Das PM, Spoelstra NS, Edgerton SM, Richer JK, Thor AD, Jones C. Aromatase induction in tamoxifen-resistant breast cancer cell lines induced by two methods. Oncol Lett. 2018;15:3532–35.
80. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer. 2004;11:643–58.
81. Wei Y, Lai X, Yu S, Chen S, Ma Y, Zhang Y, Li H, Zhu X, Yao L, Zhang J. miR-34a modulates ErbB2 in breast cancer. Cell Biol Int. 2017;41:93.
82. Wu Q, Guo L, Jiang F, Li L, Li Z, Chen F. Analysis of the miRNA expression profiles in tamoxifen-resistant human breast cancer cell lines. Anti-Cancer Drugs. 2018;29(6):539–48.
83. Xiao H, Wang Y, Xie P, Wang J, He Y, Wu JZ, Ji MH, Ma T, Qiao EQ, Ma R, Tang JH. miR-342 is associated with estrogen receptor-a expression and response to tamoxifen in breast cancer. Exp Ther Med. 2013;5:813–8.
84. Zhou Q, Zeng H, Ye P, Shi Y, Guo J, Long X. Differential microRNA profiles between fulvestrant-resistant and tamoxifen-resistant human breast cancer cells. Anti-Cancer Drugs. 2018;29(6):539–48.
85. Chen T, Berezikov E, Mano H, Inoue S. miR-378a-3p modulates tamoxifen resistance and is a novel marker of poor prognosis in breast cancer. Oncogene. 2012;31:8082–97.
86. Li S, Zhang Z, Zhang X, Zou X, Gu Y, Shen J, Zhang H, Ge X, Guan Z, Zhu Z, et al. Lower BECN1 downregulates HEI2 expression to enhance tamoxifen sensitivity and predicts a favorable outcome for ER positive breast cancer. Oncotarget. 2017;8:25166–77.
87. Gu Y, Chen T, Li G, Xu C, Xu Z, Zhang J, He K, Zheng L, Guan Z, Su X, et al. Phosphorylation of estradiol receptor by Src regulates its hormone-dependent nuclear export and cell cycle progression in breast cancer cells. Front Cell Neurosci. 2014;8:338.
88. Zou Q, Zeng H, Ye P, Shi Y, Guo J, Long X. Differential microRNA profiles during the initiation of mammary gland development. Cell Tissue Res. 2013;353:425–33.
89. Ikeda K, Horie-Inoue K, Ueno T, Suzuki T, Sato W, Shigekawa T, Osaki A, Saeki T, Berezikov E, Mano H, Inoue S. miR-378a-3p modulates tamoxifen resistance and is a novel marker of poor prognosis in breast cancer. Oncogene. 2012;31:8082–97.
90. Pancholi S, Lykkefeldt AE, Hilmi C, Banerjee S, Leary A, Drury S, Johnston S, Leary A, Drury S, Johnston S, et al. Aromatase induction in tamoxifen-resistant breast cancer. Expert Review of Endocrinology & Metabolism. 2015;10:607–17.
91. Jansen M, Rejim EA, Seuwerds AM, Rugroik-Rittser K, Look MP, Rodríguez-González FG, Heine AA, Martens JW, Sijliger S, Foekens JA, Berns E. High miR-26a and low CDCL2 levels associate with decreased E2H2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. Breast Cancer Res Treat. 2012;133:937–47.
92. Wang Y, Zhang X, Zhao Z, Kung HF, Lin MC, Dress A, Wardle F, Jiang BH, Lai M. miR-34a modulates E2Bb in breast cancer. Cell Biol Int. 2017;41:93–101.
93. Gu Y, Chen T, Li G, Xu C, Xu Z, Zhang J, He K, Zheng L, Guan Z, Su X, et al. Lower BECN1 downregulates HEI2 expression to enhance tamoxifen sensitivity and predicts a favorable outcome for ER positive breast cancer. Oncotarget. 2017;8:25166–77.
94. Zhou Q, Zeng H, Ye P, Shi Y, Guo J, Long X. Differential microRNA profiles between fulvestrant-resistant and tamoxifen-resistant human breast cancer cells. Anti-Cancer Drugs. 2018;29(6):539–48.
95. Rao X, Di Lava G, Li M, Fang F, Devlin C, Hartman-Frey C, Burow M, Ivan M, Croce CM, Nephew K. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene. 2011;30:9882–97.
96. Sansone P, Berishia M, Rajasekhar VK, Ceciarelli C, Chang Q, Strillacci A, Savini C, Shapiro L, Bowman RW, Mastroleo C, et al. Evolution of cancer stem-like cells in endocrine-resistant metastatic breast cancers is mediated by stromal microvesicles. Cancer Res. 2017;77:1927–41.
97. Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, Salisbury JD, Cheng AS, Li L, Abbosh PH, et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res. 2006;66:11954–66.
98. Nam S, Long X, Kwon C, Kim S, Nephew KP. An integrative analysis of cellular contexts, miRNAs and mRNAs reveals network clusters associated with antiestrogen-resistant breast cancer cells. BMC Genomics. 2012;13:732.
99. Liu L, Shen W, Zhu Z, Lin J, Fang Q, Ruan Y, Zhao H. Combined inhibition of EGFR and c-ABL suppresses the growth of fulvestrant-resistant breast cancer cells through miR-375-autophagy axis. Biochim Biophys Acta. 2018;1898:559–65.
100. Yu X, Luo A, Liu Y, Wang S, Li Y, Shi W, Liu Z, Qu X. MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy. Mol Cancer. 2015;14:208.
101. Vilquin P, Donini CF, Villedieu M, Grisard E, Corbo L, Bachelot T, Vendrell JA, Cohen PA. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer. Breast Cancer Res. 2015;17:13.
102. Marsi S, Liu Z, Phung S, Wang E, Yuan Y-C, Chen S. The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells. Breast Cancer Res Treat. 2010;124:89–99.
103. Bacci M, Giannori E, Fears A, Ribas R, Gao Q, Taddei ML, Pintus G, Dowsett M, Lacke CM, Martin L-A, et al. miR-155 drives metabolic reprogramming of ER+ breast cancer cells following long-term estrogen deprivation and predicts clinical response to aromatase inhibitors. Cancer Res. 2016;76:1615–26.
104. Peschiali A, Gacobbe A, Formosa A, Markert F, Ebling-Fromarone B, Levine A, Candi E, D’alessandro A, Zolla L, Melino G. miR-143 regulates hexokinase expression, promoting cancer stemness in breast cancer. Exp Ther Med. 2013;5:813–9.
113. Cheng C, Fu X, Alves P, Gerstein M. miRNA expression profiles show differential regulatory effects of microRNAs between estrogen receptor-positive and estrogen receptor-negative breast cancer. Genome Biol. 2009;10:R90.

114. Macias S, Michlewi6ski G, Cáceres JF. Hormonal regulation of microRNA biogenesis. Mol Cell. 2009;36:172–3.

115. Arpino G, Weihmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008;29:217–33.

116. Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM. Estrogen receptor–positive, progesterone receptor–negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005;97:1254–61.

117. Chou C-H, Sheerstra S, Yang C-D, Chang N-W, Lin Y-L, Liao K-W, Huang W-C, Sun T-H, Tu S-J, Lee W-H, et al. miRTarBase update 2018: a resource for experimentally validated microRNA–target interactions. Nucleic Acids Res. 2018;46:D296–302.

118. Zhou X, Marian C, Makambi KH, Kosti O, Kalliakury BV, Loffredo CA, Zheng Y-Y, Chou C-H, Shrestha S, Yang C-D, Chang N-W, Lin Y-L, Liao K-W, Huang W-C, Sun T-H, Tu S-J, Lee W-H, et al. miRTarBase update 2018: a resource for experimentally validated microRNA–target interactions. Nucleic Acids Res. 2018;46:D296–302.

119. Kolacinska A, Morawiec J, Pawlowska Z, Szemraj J, Szymanska B, Malachowska B, Morawiec Z, Morawiec-Sztandera A, Pakula L, Kubiak R, Zawilki I. Association of microRNA-93, 190, 200b and receptor status in core biopsies from stage III breast cancer patients. DNA Cell Biol. 2014;33:624–9.

120. van Schooneveld E, Wildiers H, Vergote I, Vermeulen PB, Dirix LY, Van Laere K. Estrogen receptor–positive, progesterone receptor–negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005;97:1254–61.

121. Jegg A-M, Ward TM, Iorns E, Hoe N, Zhou J, Liu X, Singh S, Landgraf R, Pegram JA, van Schooneveld E, Wildiers H, Vergote I, Vermeulen PB, Dirix LY, Van Laere K. Estrogen receptor–positive, progesterone receptor–negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005;97:1254–61.

122. Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res. 2009;11:R27.

123. Crippa E, Luca L, De Cecco L, Marchesi E, Calin GA, Radice P, Manoukian S, Peissel B, Daidone MG, Gariboldi M, Pierotti MA. miR-342 regulates BRCA1 expression through modulation of ID4 in breast cancer. PLoS One. 2014;9:e87039.

124. Ward A, Shukla K, Balwierz A, Soons Z, König R, Sahin Ö, Wiemann S. MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. J Pathol. 2014;233:368–79.

125. Pillai MM, Gillen AE, Yamamoto TM, Kline E, Schmidt S, Blake J, Ball G, Kerin MJ. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res. 2009;11:R27.

126. Veronese A, Liu X, et al. miR-145 participates with TP53 in a death–apoptosis pathway in breast cancer cells. Breast Cancer Res Treat. 2012;136:683–90.

127. Fang D, Yang H, Lin J, Teng Y, Jiang Y, Chen J, Li Y. 17β-estradiol regulates cell proliferation, colony formation, migration, invasion and promotes apoptosis by upregulating miR-9 and thus degrades MALAT-1 in osteosarcoma cell MG-63 in an estrogen receptor-independent manner. Biochem Biophys Res Commun. 2015;457:500–6.

128. Tlghman SL, Bratton MR, Segar HC, Martin EC, Rhodes LV, Li M, McLachlan JA, Wiens TE, Nephew KP, Burow ME. Endocrine disruptor regulation of microRNA expression in breast carcinoma cells. PLoS One. 2012;7:e32754.